The Bronx, NY 的 伯基特淋巴瘤 臨床試驗
6 項針對 伯基特淋巴瘤 的研究正在 The Bronx(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Montefiore Medical Center - Moses Campus, The Bronx
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Montefiore Medical Center - Moses Campus, The Bronx
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- Montefiore Medical Center PRIME, The Bronx
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Montefiore Medical Center - Moses Campus, The Bronx
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Montefiore Medical Center - Moses Campus, The Bronx
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- Montefiore Medical Center, The Bronx
其他城市的 伯基特淋巴瘤 試驗
- Houston, TX21 項研究
- Philadelphia, PA16 項研究
- Milwaukee, WI16 項研究
- Chicago, IL15 項研究
- Cincinnati, OH13 項研究
- New York City, NY13 項研究
- Atlanta, GA12 項研究
- Aurora, CO11 項研究
- Seattle, WA11 項研究
- Durham, NC10 項研究
- Boston, MA10 項研究
- Kansas City, MO10 項研究
The Bronx 的其他研究
- 非小細胞肺癌25 項研究
- 乳癌17 項研究
- 急性髓系白血病15 項研究
- 肺癌13 項研究
- 癌症(所有類型)12 項研究
- 心血管疾病12 項研究
- 心臟衰竭11 項研究
- 前列腺癌11 項研究
- 轉移性癌症9 項研究
- 大腸直腸癌9 項研究
- 頭頸部鱗狀細胞癌9 項研究
- 骨髓增生異常症候群9 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。